Future Electronics Celebrates Melanie Aussant’s 10-Year Anniversary

Future Electronics Celebrates Melanie Aussant’s 10-Year Anniversary
Future Electronics honors Melanie Aussant’s 10-year journey with the company. Now an Asset Manager for Future Lighting Solutions, Melanie’s dedication and accomplishments reflect the company’s commitment to fostering growth and greatness.

Montreal, Quebec – January 30, 2025 – Future Electronics, a global leader in electronic components distribution, is proud to celebrate Mélanie Aussant’s remarkable 10-year anniversary with the company. Her career is a shining example of the opportunities for growth and success within Future Electronics.

Mélanie began her career at Future Electronics in 2014 as a Marketing Support Representative (MSR). Her talent and determination quickly propelled her forward, earning her a promotion to Consignment Program Advocate in 2016. From 2017 to 2022, she excelled in Product Marketing for Passives before achieving her dream role as Asset Manager for Future Lighting Solutions in 2022.

“My mom worked here for many years, and I still remember coming in as a teenager when school was out,” Melanie said, reflecting on the early experiences that inspired her to join the team. “I knew even back then that I wanted to work at Future Electronics.”

Mélanie’s story isn’t just about professional success. In 2020, after years of perseverance, she achieved one of her greatest personal milestones: becoming a mother. Mélanie credits the MUHC Fertility & IVF team for their support during this journey. Her family is now eagerly awaiting the arrival of her second child in March 2025.

Outside of work, Mélanie has dedicated over 15 years to volunteering as a Scouts Leader and Commissioner with the Adventurers Association of Baden-Powell, inspiring youth with survival skills, first aid, and leadership training. She also enjoys traveling with her family, exploring the outdoors through camping and hiking, and participating in Future Electronics’ “unofficial” Book Club, which has expanded her literary horizons.

Future Electronics congratulates Mélanie Aussant on her outstanding contributions over the past 10 years. Her story exemplifies the company’s dedication to empowering employees and fostering an environment of collaboration, growth, and excellence.

For more information about Future Electronics and career opportunities, visit: https://www.FutureElectronics.com/careers

About Future Electronics:

Founded in 1968, Future Electronics is a global leader in the electronic components industry. Future Electronics’ award-winning customer service, global supply chain programs and industry-leading engineering design services have made the company a strategic partner of choice.

Headquartered in Montreal, Canada, Future Electronics operates in 159 offices across 44 countries with over 5,000 employees. Its worldwide presence powers the company’s outstanding service and efficient, comprehensive global supply chain solutions. Future Electronics is globally integrated and supported by one IT infrastructure which provides real-time inventory availability and enables fully integrated operations, sales and marketing services worldwide. In 2024, Future became a WT Microelectronics company, now dual-headquartered in both Montreal, Canada and Taipei City, Taiwan.

Future Electronics’ mission is always to Delight the Customer®. For more information visit www.FutureElectronics.com.

Media Contact
Company Name: Future Electronics
Contact Person: Jamie Singerman
Email: Send Email
Phone: 514-694-7710
Address:237 Hymus Boulevard
City: Pointe Claire
State: Quebec
Country: Canada
Website: https://www.futureelectronics.com/

Germany – 184 Existing Data Center Facilities & 38 Upcoming Data Centers Details Analyzed – Arizton

Frankfurt dominates the upcoming data center market in Germany with almost 60% of the total power capacity.

 

Arizton published latest research on the Germany existing & upcoming data center portfolio.

 

Get Exclusive Insight on the Database Now: https://www.arizton.com/market-reports/germany-data-center-portfolio

 

Germany Data Center Market Database Report Scope

Number of Existing Facilities: 184

Number of Upcoming Facilities: 38

 

This database covers the Germany data center market portfolio analysis, which will provide the following information on the colocation data centers:

  • Detailed Analysis of 184 existing data centers
  • Detailed Analysis of 38 upcoming data centers
  • Locations covered:Alsbach-Hähnlein, Berlin, Bochum, Bonn, Cologne, Dortmund, Dresden, Dusseldorf, Ellhofen, Falkenstein, Frankfurt, Göppingen, Hallstadt, Hamburg, Hanau, Hannover, Herne, Hof, Jena, Karlsruhe, Langen, Leipzig, Leverkusen, Ludwigshafen, Munich, Nuremberg, Rhein-Ruhr, Saarland, Stuttgart.
  • Existing white-floor space (square feet)
  • Upcoming white-floor space (square feet)
  • Current IT load capacity (2023)
  • Future capacity additions (2024-2028)
  • Retail Colocation Pricing
  • Quarter Rack (1/4)
  • Half Rack Cabinets (1/2)
  • Full Rack Cabinet (42U/45U/47U/etc.)
  • Wholesale colocation (per kW) pricing

 

Germany Data Center Market Overview

Germany’s data center market is primarily led by NTT DATA, the largest operator in the region, followed by industry giants Digital Realty and Equinix. Frankfurt remains the key location for data center operations in the country, with most of the existing rack capacity concentrated in the city. The growing adoption of advanced technologies such as AI is driving an increased demand for data center services, further fueling the expansion of the sector. However, data center operators are facing challenges due to stringent regulations that are becoming more complex over time. Looking ahead, Frankfurt continues to dominate the upcoming data center market, with nearly 60% of the total planned power capacity concentrated in the city, underscoring its importance as the hub for future data center development in Germany.

 

We Get in Touch with Industry Experts Across the Following Categories:

  • Data Center Contractors/Sub-Contractors (Civil, Engineering, Architecture, and others)
  • Data Center System Integrators (Power/Cooling/Physical Security/Fire Suppression-Detection Systems)
  • Data Center Developers (Colocation Service Providers)
  • Data Center Infrastructure Providers

 

Looking for More Information? Click: https://www.arizton.com/market-reports/germany-data-center-portfolio

 

Target Audience

  • Data Center Real Estate Investment Trusts (REIT)
  • Data Center Construction Contractors
  • Data Center Infrastructure Providers
  • New Entrants
  • Consultants/Consultancies/Advisory Firms
  • Corporate and Governments Agencies

 

About Our Data Center Capabilities  

Arizton’s team of principal consultants and analysts work towards publishing extensive secondary and primary research that is credible, resourceful, and data driven. With over 5 years of experience, Arizton has helped several Fortune 500 companies with data-driven insights that enabled them to expand their businesses to niche regions, added over a billion dollars in revenues, and effective go-to-market strategies. We offer various product portfolios to meet the clients’ requirements, which align with their key business strategies and identify high-value growth avenues.  

Exhaustive syndicated reports, databases, country-wise market analysis, & customized consulting projects are published by our team of exuberant and well-experienced analysts who possess exemplary skills in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research. Subscribe to our exhaustive portfolios to gain access to premium research reports at competitive prices. Partner with Arizton for your next strategic business decision and gain a competitive advantage with real-time, data-driven research.  

 

About Us:                                                  

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                       

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/germany-data-center-portfolio

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Germany – 184 Existing Data Center Facilities & 38 Upcoming Data Centers Details Analyzed – Arizton

Triple Negative Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Triple Negative Breast Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Triple Negative Breast Cancer Pipeline Outlook

 

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

  • In January 2025:- AstraZeneca:- This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab + paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. The study will use a Simon 2-Stage design to evaluate which cohorts may proceed to expansion.
  • In January 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).
  • In January 2025:- Mabwell (Shanghai) Bioscience Co., Ltd.:- This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.
  • In January 2025:- BioNTech SE:- This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
  • In January 2025:- Hoffmann-La Roche:- Study MO39874 is an open-label, Phase IIIb, single arm, global study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received chemotherapy for their unresectable locally advanced or metastatic disease.
  • DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
  • The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Promising Triple Negative Breast Cancer Pipeline Therapies such as Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

 

Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Triple Negative Breast Cancer Treatment Drugs

 

Triple Negative Breast Cancer Emerging Drugs Profile

 

  • Camrelizumab: Jiangsu HengRui Medicine

Camrelizumab (Airuika) is a humanized monoclonal antibody acts as immunomodulatory agent. It is formulated as solution for intravenous route. Camrelizumab is indicated as third-line treatment for recurrent or refractory classical hodgkin’s lymphoma, advanced hepatocellular carcinoma patients with oxaliplatin system chemotherapy, combined with pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, non-resectable locally advanced or metastatic first-line treatment of non-squamous non-small cell lung cancer (NSCLC), locally advanced or metastatic esophageal squamous cell carcinoma patients who have previously received first-line chemotherapy and whose disease has progressed or become intolerable and for the treatment of patients with advanced nasopharyngeal carcinoma who had disease progression after previous second-line and above chemotherapy or intolerable treatment. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

 

  • SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SKB264 is an innovative TROP2-directed ADC which was developed by OptiDC, a well-known international ADC R&D platform of Kelun-Biotech, using a proprietary payload-linker strategy (Kthiol design strategy) that achieves an optimized balance of ADC safety and efficacy by combining novel irreversible antibody conjugation chemistry, pH-sensitive payload release mechanisms, and site-specific moderately potent toxin molecules with a DAR of 7.4 (novel topoisomerase I inhibitors). SKB264 has received Breakthrough Therapy Designations (BTDs) from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic triple-negative breast cancer.

 

  • AK117: Akeso Biopharma

AK117, independently developed by Akeso, is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect. AK117 can bind to CD47 expressed on tumor cells and block the interaction between CD47 and SIRPα, in order to enhance the phagocytic activity of phagocytes on tumor cells, thereby inhibiting the growth of tumors. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

 

  • PLX038: ProLynx

PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC. Top1 inhibitors cause DNA breaks and kill tumors that are unable to repair the damage. Previously, Curie researchers showed that about one-third of TNBC patients have defects in DNA damage repair, and should respond to an effective SN-38-based therapy (Coussy et al., 2020). In PLX038, SN-38 is covalently bound to a circulating nanoparticle and is slowly released to provide free SN-38 with a long half-life, low Cmax, and high exposure – important facets for optimal safety and efficacy. Importantly, in preclinical studies PLX038 was shown to accumulate and be retained in solid tumors, where it slowly releases its SN-38. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

 

  • PMD-026: Phoenix Molecular Designs

PhoenixMD’s lead candidate, PMD-026, is the first RSK inhibitor being developed for the treatment of TNBC. It is a pill that is convenient for patients as opposed to intravenous delivery, the mode most commonly used to deliver chemotherapy. PMD-026 was designed for TNBC because RSK2 was specifically identified as the key kinase that drives the growth of this breast cancer subtype5, 6. PMD-026 is well-tolerated in breast cancer patients and can stop tumor growth for up to 5 months based on Phase 1 data. PFS in women with TNBC is three times longer for patients that express high levels of RSK2 activation as compared to those with low RSK2 activation. Preclinical data shows PMD-026 has the potential to be a platform technology for chemotherapy, hormone therapy and/or immunotherapy sensitization for a wide range of refractory cancers in the future. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

 

Explore groundbreaking therapies and clinical trials in the Triple Negative Breast Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Triple Negative Breast Cancer Drugs

 

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

 

Triple Negative Breast Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Unveil the future of Triple Negative Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Triple Negative Breast Cancer Market Drivers and Barriers

 

Scope of the Triple Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
  • Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Triple Negative Breast Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Triple Negative Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Camrelizumab: Jiangsu HengRui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. AK117: Akeso Biopharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PMD-026: Phoenix Molecular Designs
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Triple Negative Breast Cancer Key Companies
  18. Triple Negative Breast Cancer Key Products
  19. Triple Negative Breast Cancer- Unmet Needs
  20. Triple Negative Breast Cancer- Market Drivers and Barriers
  21. Triple Negative Breast Cancer- Future Perspectives and Conclusion
  22. Triple Negative Breast Cancer Analyst Views
  23. Triple Negative Breast Cancer Key Companies
  24. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

The Growth Mindset in Project Management: A Paradigm-Shifting Book for Project Leaders

New Book Highlights the Importance of Adaptability and Continuous Improvement in Today’s Dynamic Business Landscape.

The business world is undergoing a profound transformation marked by accelerated strategic decisions, AI-driven collaboration, and the changing expectations of diverse teams. These shifts have redefined the role of project managers, requiring a mindset that emphasizes learning, adaptation, and resilience. In their new book titled The Growth Mindset in Project Management: Building a Culture of Learning, Agility, and Collaboration in Every Project, Dr. Magda Jaworowicz and Dr. Peter Jaworowicz describe how treating failure as a learning opportunity can unlock innovation and drive organizations to remain competitive in the face of external shocks. Drawing on extensive experience in global organizations, the authors present a practical framework for project managers, team leaders, and business professionals looking to thrive in an environment where hybrid work, artificial intelligence, and shifting talent needs have become the norm.

The authors underscore that agility is no longer a “nice-to-have” quality but an essential practice in modern project leadership. They argue that embracing a growth mindset allows leaders to break barriers and build resilient cultures capable of navigating unprecedented levels of uncertainty and complexity. The book covers topics such as establishing a solid growth mindset foundation, applying adaptive stakeholder management techniques, and leveraging AI to transform traditional project management.

In one section, the authors present the “golden rules” of growth mindset project management and offer guidance on shaping a dynamic, growth-oriented framework. Readers will learn how to foster continuous improvement, encourage product innovation, and implement systems for ongoing learning. The discussion spans organizational power structures, hybrid collaboration, and talent management, all of which play vital roles in delivering successful outcomes. The comprehensive content is grounded in the latest research and enriched by the authors’ multicultural perspectives, gained from managing strategic initiatives for prominent global companies across the U.S., Asian, and European markets.

“The book explores how adopting a growth mindset can transform project management. It covers the golden rules for implementing a growth mindset and managing stakeholders effectively. It offers a fresh perspective on project management,” commented Dr. Magda Jaworowicz, author. “In our book, we propose building a dynamic framework for continuous improvement, product innovation, and learning to make the project management process more flexible. An adaptive approach is critical in today’s business ecosystem,” added Dr. Piotr Jaworowicz, co-author.

For more information and to purchase the book, please visit https://magdajaworowicz.com/growth-mindset-book-1.

About the Authors

Magda and Peter Jaworowicz are project management professionals with advanced degrees in Communication and Media Studies, as well as MBAs and PMP and PRINCE2 certifications. They have managed high-level projects for leading technology and retail companies, where they have seen firsthand how a growth mindset can drive both individual and organizational success. Their shared passion for transforming workplace cultures led them to write The Growth Mindset in Project Management in an effort to empower leaders, teams, and businesses worldwide.

Media Contact
Company Name: Magda and Peter Jaworowicz
Contact Person: Magda and Peter Jaworowicz
Email: Send Email
Phone: 510 2448163
Country: United States
Website: https://magdajaworowicz.com/growth-mindset-book-1

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Growth Mindset in Project Management: A Paradigm-Shifting Book for Project Leaders

Microencapsulation Market: Latest Innovations and Emerging Opportunities (2024-2029)

“MarketsandMarkets™”
Microencapsulation Market by Shell Material (Polymers, Gums & Resins, Lipids, Carbohydrates, and Proteins), Technology, Core Material, Core Material Form, End-Use Industry, Functionality, and Region – Global Forecast to 2029

The global microencapsulation market is estimated at USD 15.38 billion in 2024 and is projected to reach USD 24.07 billion by 2029, at a CAGR of 9.4% from 2024 to 2029. An increase in applications of microencapsulation is due to its potential industries across pharmaceutical, food, and personal care products. For instance, within the pharmaceutical industry, controlled drug delivery will streamline with improved effectiveness on treatment outcomes since active ingredients will now be released at specific locations and times within the body, averting side effects while improving patient compliance. Protecting sensitive ingredients such as vitamins, minerals, and probiotics from degradation, thus preserving stability and efficacy till the food is consumed, microencapsulation in the food industry shows an important aspect concerning fortified and functional foods that show an increasing demand these days due to health consciousness among consumers. Improved efficiency and lower production costs resulted from advancements in microencapsulation technologies, such as spray drying and coacervation, making the technology more accessible. This increased the demand for innovative, sustainable, and high-quality products across these industries, pushing the growth of the global microencapsulation market.

Microencapsulation Market

Microencapsulation Market Drivers: Demand for Functional Foods

Health-conscious consumers are seeking more than just basic nutrition from food products; the integration of these essential nutrients, probiotics, vitamins, and minerals within food products using microencapsulation technology is particularly enhancing their functional properties. For instance, omega-3 fatty acid-enriched products are gaining recognition because more and more health-conscious consumers are seeking these oils as they are usually drawn from fish oil. Microencapsulation protects the oil from oxidation and degradation and thus preserves its efficacy while increasing shelf life. In May 2024, dsm-firmenich (Switzerland) announced the launch of Humiome® B2, the world’s first ‘biotic’ vitamin, at Vitafoods Europe 2024. Utilizing patented Microbiome Targeted Technology™, this microencapsulation approach ensures targeted delivery of vitamin B2 to the colon, enhancing bioavailability and supporting gut health by nourishing beneficial microbiota, emphasizing holistic health.

This has the additional advantage of being in line with the clean-label trend, wherein consumers prefer fewer additives and preservatives. Microencapsulation thus masks undesirable tastes or odors accompanying certain ingredients, making it possible for manufacturers to include beneficial components without compromising flavor. With the functional food market in full bloom and driven by changing consumer preferences, microencapsulation technology is likely to take center stage in product development and innovation.

Microencapsulation Market Opportunities: Technological Advancements

A new technological approach has been attained with the integration of microencapsulation and artificial intelligence. This technology, along with various biomedical applications, promises a bright future for the collection of industries so involved. Microencapsulation is the enclosure of cells or the active constituent within a polymeric semi-permeable membrane, which allows for controlled release and protects cells and constituents from environmental stimuli. The importance of this method goes a long way in medicine; particularly in regenerative medicine, for it has enabled the improvement in stem cell viability and functionality, tissue repair, and controlled drug delivery.

Incorporation of AI in microencapsulation processes will be efficient in optimizing the process while having precision. The learning algorithms of machines can be used to sense and differentiate microcapsules during manufacture, thereby exercising quality control by segregating desirable capsules from waste materials. This enables doubling the production as well as enhancing yield. Further, AI will model and predict the optimal encapsulation conditions, such as polymer selection and environmental parameters, resulting in better output on the basis of cell viability.

Extensive datasets analyzed from experiments of microencapsulation can help in the identification of patterns and correlations usually overlooked by traditional methods. The synergy that may come from microencapsulation and AI would help revolutionize the field of regenerative medicine as well as drug delivery systems that enable therapies microencapsulated to be far more effective while addressing complex medical challenges.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=83597438

The food and beverage segment are the fastest-growing end user in the microencapsulation market.

Advancements in demand for convenience foods by consumers have promoted manufacturers to create microencapsulation that improves the stability and shelf life of ingredients such as vitamins and probiotics. For instance, probiotic-protected yogurt is a product whose probiotics are microencapsulated so that they become effective until they are consumed.

In addition, the demands placed upon microencapsulation by increasing requirements for functional foods having added benefits beyond plain nutrition help to dictate its use. Such examples include fortified beverages and snack bars, which utilize microencapsulated vitamins or minerals to maximize their health benefit beyond basic needs for immunity or energy. For example, In January 2023, BASF SE (Germany) developed a unique microencapsulation method for vitamins A and D, used in flour and sugar fortification. This process not only extends shelf life but also improves flowability and reduces dust during production, making it highly advantageous for food producers.

The technological improvements in microencapsulation techniques enhance further scalability for companies. For example, DuPont (US) and others are developing novel techniques to control the release of flavors and nutrients in food and beverages, thus enhancing its appeal in the market. The segment in the microencapsulation market, with respect to health, convenience, and innovation, is driving this rapid growth.

The Asia Pacific region is anticipated to experience the fastest growth between 2024 and 2029.

The demand in countries like China, India, and Japan, for fortified and functional products from the food and beverage sector is likely to be the driving force behind growth. As health awareness increases and the trend shifts to healthier lifestyles, vitamins, probiotics, and other nutrients call for improved stability and bioavailability through microencapsulation.

More opportunities for microencapsulation technologies emerge in the Asia Pacific as the pharmaceutical and cosmetics industries grow in the region. Companies in these sectors can rely heavily on encapsulation techniques to enhance controlled active ingredients, including drug formulations and skincare formulas. Most importantly, the governments in the region have tightened the policy of local production with incentives and investments in innovation, which attracts major global players to set up manufacturing and R&D facilities in the regions. For instance, In April 2021, BASF SE (Germany) announced the groundbreaking for the third phase of its Innovation Campus Shanghai, investing approximately USD 296.8 million. This expansion includes new R&D facilities and an academic-sounding board to enhance collaboration with top universities, strengthening BASF’s innovation capabilities to meet the needs of growing industries in Asia.

Leading Microencapsulation Manufacturers:

The report profiles key players such as BASF (Germany), FrieslandCampina (Netherlands), dsm-firmenich (Switzerland), Givaudan (Switzerland), International Flavors & Fragrances Inc. (US), Sensient Technologies Corporation (US), Balchem Corp. (New Jersey), Ingredion (US), Kerry Group plc (Ireland), Symrise (Germany), DuPont (US), Cargill Incorporated (US), Syngenta (Switzerland), Lycored (New Jersey), Koehler Group (US).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=83597438

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

 

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/microencapsulation-market-83597438.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Microencapsulation Market: Latest Innovations and Emerging Opportunities (2024-2029)

Advanced Cervical Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Advanced Liver Cancer Treatment Landscape. Click here to read more @ Advanced Liver Cancer Pipeline Outlook

 

Key Takeaways from the Advanced Cervical Cancer Pipeline Report

  • In January 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival.
  • In January 2025:- AstraZeneca:- A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical). Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.
  • In January 2025:- DualityBio Inc.:- This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts the standard “3+3” design to identify: the MTD and/or RP2D of DB-1310 as monotherapy, the RCD_A of DB-1310 in combination with trastuzumab and the RCD_B of DB-1310 in combination with Osimertinib; Phase 2a is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors treated with DB-1310 as monotherapy or in combination with trastuzumab or in combination with Osimertinib.
  • In January 2025:- RAPT Therapeutics Inc.:- The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.
  • In January 2025:- Amgen:- The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
  • DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
  • The leading Advanced Cervical Cancer Companies such as AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
  • Promising Advanced Cervical Cancer Pipeline Therapies such as Durvalumab, Cisplatin, Carboplatin, IBI310, and others.

 

Stay informed about the cutting-edge advancements in Advanced Cervical Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Cervical Cancer Clinical Trials Assessment

 

Advanced Cervical Cancer Emerging Drugs Profile

  • Imfinzi (durvalumab): AstraZeneca

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy, and is the global standard of care in this setting based on the PACIFIC Phase III trial. Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer based on the CASPIAN Phase III trial. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with small cell lung cancer, NSCLC, bladder cancer, several gastrointestinal cancers, ovarian cancer, endometrial cancer and other solid tumours. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

 

  • Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

 

  • Andes 1537: Andes Biotechnologies

Andes-1537, a proprietary antisense oligonucleotide designed by Andes Biotechnology, is the Company’s most advanced investigational drug candidate and the first to enter a human clinical study. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cervical Cancer.

 

Learn more about Advanced Cervical Cancer Drugs opportunities in our groundbreaking Advanced Cervical Cancer Research and development projects @ Advanced Cervical Cancer Unmet Needs

 

Advanced Cervical Cancer Companies

AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.

 

Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Advanced Cervical Cancer Pipeline Products have been categorized under various Molecule types such as-

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Discover the latest advancements in Advanced Cervical Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Cervical Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Advanced Cervical Cancer Pipeline Report

  • Coverage- Global
  • Advanced Cervical Cancer Companies- AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
  • Advanced Cervical Cancer Pipeline Therapies- Durvalumab, Cisplatin, Carboplatin, IBI310, and others.
  • Advanced Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Cervical Cancer Therapeutics Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Cervical Cancer Pipeline on our website @ Advanced Cervical Cancer Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Cervical Cancer: Overview
  4. Advanced Cervical Cancer Pipeline Therapeutics
  5. Advanced Cervical Cancer Therapeutic Assessment
  6. Advanced Cervical Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Advanced Cervical Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Durvalumab: AstraZeneca
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Dostarlimab: GlaxoSmithKline
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Andes 1537: Andes Biotechnologies
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Advanced Cervical Cancer Key Companies
  20. Advanced Cervical Cancer Key Products
  21. Advanced Cervical Cancer- Unmet Needs
  22. Advanced Cervical Cancer- Market Drivers and Barriers
  23. Advanced Cervical Cancer- Future Perspectives and Conclusion
  24. Advanced Cervical Cancer Analyst Views
  25. Advanced Cervical Cancer Key Companies
  26. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/surgical-mask-respirator-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Cervical Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

Netherlands – 125 Existing Data Center Facilities & 40 Data Center Operators Details Analyzed – Arizton

Digital Realty and Equinix are the top data center operators in the Netherlands market

 

Arizton published latest research on the Netherlands existing & upcoming data center portfolio.

Get Exclusive Insight on the Database Now: https://www.arizton.com/market-reports/netherlands-data-center-portfolio

 

Netherlands Data Center Market Database Report Scope

Number of Existing Facilities: 125

Number of Upcoming Facilities: 11

 

This database covers the Netherlands data center market portfolio analysis, which will provide the following information on the colocation data centers:

  • Detailed Analysis of 125 existing data centers
  • Detailed Analysis of 11 upcoming data centers
  • Location covered: Aalsmeer, Almere, Almere, Alphen aan den Rijn, Amsterdam, Apeldoorn, Arnhem, Delft, Deventer, Dronten, Ede, Eemshaven, Eindhoven, Enschede, Geleen, Gemert, Goes, Groningen, Haarlem, Hague, Hengelo, Hilversum, Hoogersmilde, IJsselstein, Leeuwarden, Lelystad, Limburg, Loon op Zand, Maastricht, Markelo, Megen, Meppel, Mierlo, Naaldwijk, Nieuwegein, Oude Meer, Roermond, Roosendaal, Rotterdam, s-Hertogenbosch, Steenbergen, Tjerkgaast, Ugchelen, Utrecht, Waalwijk, Wormer, Zwolle.
  • Existing white-floor space (square feet)
  • Upcoming white-floor space (square feet)
  • Current IT load capacity (2024)
  • Future capacity additions (2025-2028)
  • Retail Colocation Pricing
  • Quarter Rack (1/4)
  • Half Rack Cabinets (1/2)
  • Full Rack Cabinet (42U/45U/47U/etc.)
  • Wholesale colocation (per kW) pricing

 

We Get in Touch with Industry Experts Across the Following Categories:

  • Data Center Contractors/Sub-Contractors (Civil, Engineering, Architecture, and others)
  • Data Center System Integrators (Power/Cooling/Physical Security/Fire Suppression-Detection Systems)
  • Data Center Developers (Colocation Service Providers)
  • Data Center Infrastructure Providers

 

Netherlands Existing & Upcoming Data Center Market Report Insights

The data center market in the Netherlands is characterized by a significant gap between existing and upcoming capacity, with current IT power capacity almost double that of the anticipated new data centers. The market is primarily dominated by leading operators such as Digital Realty and Equinix, both of whom hold substantial shares in the country. Amsterdam stands out as the focal point, with around 90% of the upcoming rack capacity concentrated in the city. Existing data centers, which number 125 facilities, provide a detailed snapshot of the market, including key information such as the location, operator or owner, facility name, white-floor area, IT load capacity, rack capacity, year of operations, design standards (ranging from Tier I to Tier IV), and the redundancy levels for power and cooling systems. Meanwhile, 11 upcoming data centers are currently under development or in the planning stages. These projects are accompanied by detailed investment snapshots, including breakdowns for electrical, mechanical, and construction infrastructure investments, as well as the expected opening year. This comprehensive data highlights both the current state and the projected growth of the data center market in the Netherlands, with Amsterdam continuing to be the central hub for new developments.

 

Looking for More Information? Click: https://www.arizton.com/market-reports/netherlands-data-center-portfolio

 

Target Audience

  • Data Center Real Estate Investment Trusts (REIT)
  • Data Center Construction Contractors
  • Data Center Infrastructure Providers
  • New Entrants
  • Consultants/Consultancies/Advisory Firms
  • Corporate and Governments Agencies

 

About Our Data Center Capabilities  

Arizton’s team of principal consultants and analysts work towards publishing extensive secondary and primary research that is credible, resourceful, and data driven. With over 5 years of experience, Arizton has helped several Fortune 500 companies with data-driven insights that enabled them to expand their businesses to niche regions, added over a billion dollars in revenues, and effective go-to-market strategies. We offer various product portfolios to meet the clients’ requirements, which align with their key business strategies and identify high-value growth avenues.  

Exhaustive syndicated reports, databases, country-wise market analysis, & customized consulting projects are published by our team of exuberant and well-experienced analysts who possess exemplary skills in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research. Subscribe to our exhaustive portfolios to gain access to premium research reports at competitive prices. Partner with Arizton for your next strategic business decision and gain a competitive advantage with real-time, data-driven research.  

 

About Us:                                                  

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                       

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/netherlands-data-center-portfolio

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Netherlands – 125 Existing Data Center Facilities & 40 Data Center Operators Details Analyzed – Arizton

Profit for Veterans Launches to Support Disabled First Responders and Veterans

New Initiative Donates 100% of Book Profits to Assist Heroes Transitioning to Civilian Success.

Profit for Veterans, founded by retired executive, educator, and entrepreneur Martin Lund, has officially launched with a mission to support veterans and first responders. The initiative donates 100% of profits from Lund’s books to programs that help these individuals overcome challenges and build successful post-service lives.

With a distinguished career spanning corporate leadership, education, and real estate investment, Martin Lund brings decades of experience to this philanthropic endeavor. His books, Foreclosure Solutions: The Ultimate Guide to Foreclosure Defense and How to Buy and Sell Foreclosure Homes for Profit, provide invaluable financial insights based on his firsthand expertise. By directing all proceeds from these publications toward assisting veterans and first responders, Profit for Veterans aims to empower those who have sacrificed for their country and communities.

Through this initiative, the organization focuses on providing financial literacy, career resources, and support programs that enable disabled veterans and first responders to thrive. Many of these individuals face unique challenges as they transition to civilian life, and Profit for Veterans seeks to bridge the gap with practical assistance and opportunities for long-term success.

Lund’s extensive background in business and education informs his approach to this mission. He previously served as Chief Financial Officer and Board Member at Tiffany & Company for two decades before shifting into real estate, where he specialized in acquiring and selling distressed properties. In addition to his executive experience, he has taught at New York University and the American Real Estate School, sharing his knowledge with aspiring professionals.

The two books at the center of this initiative offer a comprehensive guide to navigating foreclosure and real estate investment. Foreclosure Solutions: The Ultimate Guide to Foreclosure Defense serves as a step-by-step manual for homeowners facing foreclosure, as well as professionals assisting them. How to Buy and Sell Foreclosure Homes for Profit provides expert strategies for those interested in real estate investment, focusing on maximizing profitability while minimizing risk. Both books are available in Kindle editions on Amazon.

“Our veterans and first responders have given so much to serve and protect us. Profit for Veterans is my way of giving back, using my experience and resources to provide real, tangible support,” said Martin Lund. “Every book purchased is more than just a financial guide—it’s a direct contribution to helping these heroes build successful futures.”

By purchasing these books, readers not only gain valuable knowledge but also contribute to a cause that makes a real difference. Profit for Veterans is committed to using these proceeds to fund meaningful initiatives that equip veterans and first responders with the skills and opportunities they need to succeed.

For more information visit https://profitforveterans.com.

Media Contact
Company Name: Profit for Veterans
Contact Person: Martin Lund
Email: Send Email
Phone: 516-319-5487
Country: United States
Website: https://profitforveterans.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Profit for Veterans Launches to Support Disabled First Responders and Veterans

Advanced Liver Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Advanced Liver Cancer Pipeline Insight” Report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced liver cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Advanced Liver Cancer Treatment Landscape. Click here to read more @ Advanced Liver Cancer Pipeline Outlook

 

Key Takeaways from the Advanced Liver Cancer Pipeline Report

  • In January 2025:- Hoffmann-La Roche:- This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
  • In January 2025:-Tango Pharmaceuticals Inc.:- This is a Phase 1/2 multi-center, open label study in solid tumor patients who have a confirmed homozygous MTAP deletion in their tumor. The Phase 1 portion is a dose escalation study of oral TNG462 administered as a single agent and in combination with pembrolizumab in patients with confirmed MTAP-deleted solid tumors. In Phase 2, 6 expansion arms defined by confirmed MTAP-deleted tumor types will enroll in parallel at the RP2D(s) of TNG462 and in combination. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.
  • In January 2025:- AstraZeneca:- This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participaants with advanced unresectable HCC. Participants must not have received any prior systemic therapy for HCC. Participants may have previously received locoregional therapy (LRT) but must no longer be suitable for additional LRT. Any local treatment needs to have been completed at least 4 weeks prior to initiation of treatment. The study consists of 4 periods: screening (Day-28 to Day -1), Treatment period, safety follow-up and survival follow-up.
  • In January 2025:- Polaris Group:- Safety will be evaluated by laboratory tests, vital sign measurements, physical examinations and subject medical history which will be performed to detect new abnormalities and any deterioration in pre-existing conditions. Efficacy will be determined by overall survival, progression free survival, pharmacodynamics (peripheral blood arginine and citrulline levels) and immunogenicity (antibodies to ADI-PEG 20).
  • DelveInsight’s Advanced Liver Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Liver Cancer treatment.
  • The leading Advanced Liver Cancer Companies such as Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd., and others.
  • Promising Advanced Liver Cancer Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab, and others.

 

Stay informed about the cutting-edge advancements in Advanced Liver Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Liver Cancer Clinical Trials Assessment

 

Advanced Liver Cancer Emerging Drugs Profile

 

  • Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson’s mechanism of action is mediated via deregulation of the NF-?B and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.

 

  • ADI-PEG20: Polaris Pharmaceuticals

Pegylated arginine deiminase (ADI-PEG20) is a novel anticancer enzyme that produces depletion of arginine, which is a nonessential amino acid in humans. Certain tumors, such as malignant melanoma and hepatocellular carcinoma, are auxotrophic for arginine. These tumors that are sensitive to arginine depletion do not express argininosuccinate synthetase, a key enzyme in the synthesis of arginine from citrulline. ADI-PEG20 appears to show inhibitory effects on human melanomas and hepatocellular carcinomas. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.

 

  • SRF388: Surface Oncology

SRF388 is a fully human IgG1 blocking antibody to IL-27 with potential to promote immune activation in the tumor microenvironment. The immunoregulatory cytokine IL-27 upregulates inhibitory immune checkpoint receptors (eg, PD-L1, TIGIT) and downregulates proinflammatory cytokines (eg, IFN?, TNFa). Currently, the drug is in the Phase II stage of development to treat Advanced liver cancer.

 

  • TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. Currently, the drug is in the Phase I stage of development to treat Advanced liver cancer.

 

Learn more about Advanced Liver Cancer Drugs opportunities in our groundbreaking Advanced Liver Cancer Research and development projects @ Advanced Liver Cancer Unmet Needs

 

Advanced Liver Cancer Companies

Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd, and others.

 

Advanced liver cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Advanced Liver Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Discover the latest advancements in Advanced Liver Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Liver Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Advanced Liver Cancer Pipeline Report

  • Coverage- Global
  • Advanced Liver Cancer Companies- Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd., and others.
  • Advanced Liver Cancer Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab, and others.
  • Advanced Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Liver Cancer Pipeline on our website @ Advanced Liver Cancer Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced liver cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced liver cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Namodenoson: Can-Fite BioPharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Product Name: Company Name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced liver cancer Key Companies
  21. Advanced liver cancer Key Products
  22. Advanced liver cancer- Unmet Needs
  23. Advanced liver cancer- Market Drivers and Barriers
  24. Advanced liver cancer- Future Perspectives and Conclusion
  25. Advanced liver cancer Analyst Views
  26. Advanced liver cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/nk-cell-therapy-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Liver Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape. It covers the Metastatic Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Metastatic Breast Cancer Research. Learn more about our innovative pipeline today! @ Metastatic Breast Cancer Pipeline Outlook

 

Key takeaways from the Metastatic Breast Cancer Pipeline Report

  • In January 2025:- Oncolytics Biotech:- The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized (cancer that has spread in your body). The study will investigate if pelareorep in combination with paclitaxel and avelumab is more effective than paclitaxel alone, or pelareorep and paclitaxel. The safety of the combination treatments will also be evaluated.
  • In January 2025:- Eli Lilly and Company:- The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
  • In January 2025:- Allarity Therapeutics:- The Phase 2 study is using 2x-121 DRP® biomarker in metastatic breast cancer patients to identify patients likely to respond to and benefit from treatment with 2X-121. 2X-121 is a small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells. The PARP inhibitor demonstrated clinical activity in a prior Phase 1 study in a number of solid tumors. 2X-121 has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2. The molecule is also active in P-glycoprotein expressing cells, suggesting it may overcome some of the PARP inhibitor resistance.
  • DelveInsight’s Metastatic Breast Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Metastatic Breast Cancer treatment.
  • The leading Metastatic Breast Cancer Companies working in the market include Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.
  • Promising Metastatic Breast Cancer therapies in the various stages of development include Tucatinib, Capecitabine, Trastuzumab, Palifosfamide, Bavituximab, NK105, Paclitaxel, Navelbine, Herceptin, and others

 

Stay informed about the cutting-edge advancements in Metastatic Breast Cancer treatments. Download for updates and be a part of the revolution in care @ Metastatic Breast Cancer Clinical Trials Assessment

 

Metastatic Breast Cancer Emerging Drugs Profile

  • Giredestrant: Roche

Giredestrant is a next generation investigational Selective estrogen receptor degrader (SERD), designed to fully block ER signalling with robust receptor occupancy. Oestrogen encourages HR-positive breast cancer cells to grow by attaching to the ER. Giredestrant works by blocking this receptor to prevent the action of oestrogen, and in the process causes the receptor to be degraded. This investigational medicine has also shown efficacy regardless of ESR1 mutation status (mutations in the ESR1 gene are important mechanisms of resistance to hormone therapy).

 

  • Disitamab Vedotin: RemeGen

Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells.

 

  • EndoTAG®-1 (SB05): SynCore Biotechnology

SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.

 

  • Stenoparib (2X-121): Allarity Therapeutics

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Given its novel mechanism of action and ability to cross the blood brain barrier (BBB), plus its associated DRP®, stenoparib is poised to yield improved efficacy, lower toxicity, and lower drug resistance compared the other late-stage or marketed PARP inhibitors.

 

Learn more about Metastatic Breast Cancer Drugs opportunities in our groundbreaking Metastatic Breast Cancer Research and development projects @ Metastatic Breast Cancer Unmet Needs

 

Metastatic Breast Cancer Companies

Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.

 

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Metastatic Breast Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Discover the latest advancements in Metastatic Breast Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Metastatic Breast Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Metastatic Breast Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Metastatic Breast Cancer Companies- Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.
  • Metastatic Breast Cancer Therapies- Tucatinib, Capecitabine, Trastuzumab, Palifosfamide, Bavituximab, NK105, Paclitaxel, Navelbine, Herceptin, and others.

 

For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Breast Cancer Pipeline on our website @ Metastatic Breast Cancer Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Breast Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Giredestrant: Roche
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Stenoparib – Allarity Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ARV-471: Arvinas
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Breast Cancer Key Companies
  21. Metastatic Breast Cancer Key Products
  22. Metastatic Breast Cancer- Unmet Needs
  23. Metastatic Breast Cancer- Market Drivers and Barriers
  24. Metastatic Breast Cancer- Future Perspectives and Conclusion
  25. Metastatic Breast Cancer Analyst Views
  26. Metastatic Breast Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/novel-drug-delivery-devices

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight